Newly diagnosed diabetes with weight loss and a normal-looking glucose on paper
A 52-year-old man presents with 3 months of polyuria, polydipsia, and 8 kg unintentional weight loss. BMI 22 kg/m². Fasting glucose 7.4 mmol/L (133 mg/dL), HbA1c 6.3%, random glucose 11.8 mmol/L (212 mg/dL). He has a strong family history of type 2 diabetes. Physical exam is unremarkable; no acanthosis nigricans. C-peptide is 0.6 ng/mL (low-normal), and GAD-65 antibodies are pending. Renal and liver function are normal. He is eager to start 'the new weight-loss injection' and asks about insulin.
1. Does this patient meet diagnostic criteria for diabetes? Explain how the fasting glucose, random glucose, and HbA1c should be interpreted together, including the discordance.
Read the worked answer
Diagnosis: diabetes mellitus is confirmed.
Criteria (ADA/WHO)
- Fasting plasma glucose ≥7.0 mmol/L (126 mg/dL), OR
- 2-hour plasma glucose ≥11.1 mmol/L (200 mg/dL) during OGTT, OR
- Random plasma glucose ≥11.1 mmol/L with classic symptoms (polyuria, polydipsia, weight loss), OR
- HbA1c ≥6.5% (48 mmol/mol).
Applying to this patient
- Fasting glucose 7.4 mmol/L meets the threshold.
- Random glucose 11.8 mmol/L with classic symptoms independently meets criteria.
- HbA1c 6.3% is in the prediabetes range and does not meet the diabetes threshold.
Why the discordance matters
- HbA1c reflects average glycemia over ~3 months but is affected by hemoglobinopathies, anemia, recent blood loss, hemolysis, and altered red cell turnover. In a patient with rapid weight loss and possible recent illness, HbA1c can underestimate true glycemia.
- A single HbA1c below threshold does not exclude diabetes when fasting and random glucose plus symptoms meet criteria.
- Do not repeat HbA1c to 'confirm' - the diagnosis is already established by two independent criteria. Instead, investigate the cause of the HbA1c-glucose discordance if clinically relevant (CBC, reticulocyte count, hemoglobin electrophoresis).
2. Given the weight loss, low BMI, low C-peptide, and pending antibodies, how would you classify his diabetes and what are the immediate management priorities? Address his request for a GLP-1 receptor agonist and for insulin.
Read the worked answer
Classification
- The phenotype - lean, marked weight loss, low C-peptide, strong family history - raises the possibility of adult-onset type 1 diabetes (LADA) or ketosis-prone/atypical diabetes, though type 2 remains possible.
- Low C-peptide (0.6 ng/mL) suggests reduced beta-cell reserve; this is atypical for classic type 2 diabetes with this BMI.
- GAD-65 antibodies will help distinguish autoimmune diabetes; if positive, treat as type 1.
- Consider pancreatic diabetes (type 3c) if there is any history of pancreatitis, alcohol use, or abdominal symptoms - check fecal elastase and imaging if suspected.
- MODY is less likely given the low C-peptide and weight loss, but family history warrants consideration if antibodies are negative.
Immediate priorities
- Assess for ketosis - check blood or urine ketones and a venous blood gas. Weight loss with low C-peptide raises concern for impending DKA.
- Start insulin if ketosis is present or if C-peptide is very low with symptomatic hyperglycemia. Basal insulin is appropriate; educate on sick-day rules and hypoglycemia.
- Glucose monitoring and diabetes education.
- Screen for complications (retinopathy, nephropathy, neuropathy) once stable.
Addressing his requests
- GLP-1 receptor agonist: not first-line in suspected type 1/LADA because of the risk of DKA and the lack of beta-cell reserve; it is also inappropriate as a weight-loss agent in a patient who is already lean and losing weight. If antibodies are negative and type 2 is confirmed, it could be considered later, but weight loss is a warning sign here, not a therapeutic goal.
- Insulin: he may need it, but the decision should be driven by ketosis risk and C-peptide, not by his preference alone. Explain that insulin is the safest choice if beta-cell function is failing, and that it can be tapered if his classification changes.
3. The GAD-65 antibody returns positive. How does this change your long-term plan, and what counseling and monitoring would you provide?
Read the worked answer
Reclassification: adult-onset autoimmune diabetes (LADA/type 1 diabetes).
Management changes
- Insulin is the mainstay - plan for basal-bolus or, initially, basal insulin with rapid-acting insulin at meals as beta-cell function declines.
- Stop any glucose-lowering agents that are inappropriate (e.g., sulfonylureas accelerate beta-cell failure; GLP-1 receptor agonists are not indicated).
- Metformin is generally not indicated in type 1 unless there is insulin resistance.
Counseling
- Explain the autoimmune nature and the need for lifelong insulin.
- Sick-day rules: never omit insulin during illness; check ketones; seek help for vomiting.
- Hypoglycemia awareness and treatment.
- Screening for associated autoimmune conditions: thyroid disease (TSH, anti-TPO), celiac disease (tTG-IgA), and adrenal insufficiency if symptoms suggest (21-hydroxylase antibodies).
- Diabetes education and dietician referral.
Monitoring
- HbA1c every 3 months initially.
- Annual retinal screening, urine albumin-to-creatinine ratio, and foot exam.
- Consider continuous glucose monitoring if available, given insulin requirements and hypoglycemia risk.
- Reassess C-peptide periodically; declining levels predict increasing insulin needs.
Prognosis discussion
- Reassure that with good control, complication risk is reduced; emphasize that his weight loss was a disease symptom, not a reason to pursue weight-loss drugs.